Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Locally Advanced (Unresectable) or Metastatic Solid Tumors

Tundra lists 3 Locally Advanced (Unresectable) or Metastatic Solid Tumors clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07612189

A Phase 1 Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).

Gender: All

Ages: 18 Years - Any

Updated: 2026-05-28

4 states

Locally Advanced (Unresectable) or Metastatic Solid Tumors
RECRUITING

NCT07612176

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).

Gender: All

Ages: 18 Years - Any

Updated: 2026-05-28

4 states

Locally Advanced (Unresectable) or Metastatic Solid Tumors
RECRUITING

NCT05978492

A Study of TXN10128 in Subjects With Solid Tumors

This is a phase I clinical trial to primarily evaluate the safety, tolerability, and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity of investigational product, TXN10128. The target subjects will be consisted of patients with locally advanced (unresectable) or metastatic soild tumors. This study includes a dose-escalation part and a dose-expansion part, and a TXN10128 monotherapy part and a TXN10128 + Irinotecan or Paclitaxel combination therapy part.

Gender: All

Ages: 19 Years - Any

Updated: 2025-04-24

3 states

Locally Advanced (Unresectable) or Metastatic Solid Tumors